Krystal Biotech (KRYS) Price & Analysis

Compare

582 Followers

KRYS Stock Chart & Stats

$197.93

-$3.73(-2.33%)

At close: Jan 08 4:00 PM EST

$197.93

-$3.73(-2.33%)

Day’s Range― - ―

52-Week Range$122.80 - $212.98

Previous CloseN/A

Volume44.50K

Average Volume (3M)320.16K

Market Cap

$5.80B

Enterprise Value$4.54B

Total Cash (Recent Filing)$731.07M

Total Debt (Recent Filing)$9.51M

Price to Earnings (P/E)30.0

Beta0.78

Next Earnings

Mar 02, 2026

EPS Estimate

1.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.66

Shares Outstanding28,997,519

10 Day Avg. Volume390,648

30 Day Avg. Volume320,157

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.73

Price to Sales (P/S)15.42

P/FCF Ratio37.58

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue12.18

Enterprise Value/Gross Profit12.97

Enterprise Value/Ebitda26.55

Forecast

1Y Price Target

$221.00

Price Target Upside11.66% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline DevelopmentPipeline development continues to deliver with key updates and upcoming catalysts expected to drive future growth.

Revenue GrowthVyjuvek’s $97.8M revenue slightly beat the estimates, driven by early contributions from Germany sales.

Sales ExpansionThe US salesforce expansion appears to be positively impacting patient starts beyond the centers-of-excellence, given ~40 reimbursement approvals this quarter, which could re-invigorate the sales ramp over time.

Bears Say

Krystal Biotech News

Krystal Biotech price target raised to $198 from $166 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $198 from $166 and...

5d ago

KRYS

Krystal Biotech price target raised to $220 from $216 at Chardan

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $220 from $216 and keeps a Buy...

5d ago

KRYS

Krystal Biotech price target raised to $217 from $212 at Clear Street

Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $217 from $212 and keeps a...

5d ago

KRYS

Krystal Biotech sees FY25 non-GAAP R&D, SG&A expense $145M-$155M

07:05 EST Krystal Biotech (KRYS) sees FY25 non-GAAP R&D, SG&A expense $145M-$155M Published first on TheFly – the...

6d ago

KRYS

Krystal Biotech reports Q3 EPS $2.66, consensus $1.12

Reports Q3 revenue $97.8M, consensus $93.42M. “It is immensely gratifying to see a growing number of DEB patients...

6d ago

KRYS

Krystal Biotech price target raised to $224 from $189 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Krystal Biotech (KRYS) to $224 from $189 and...

23d ago

KRYS

Krystal Biotech price target raised to $255 from $182 at BofA

BofA raised the firm’s price target on Krystal Biotech (KRYS) to $255 from $182 and keeps a Buy...

23d ago

KRYS

Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector

Krystal Biotech (KRYS) announced that the United States Food and Drug Administration granted platform technology designation to the...

26d ago

KRYS

Krystal Biotech’s Earnings Call Highlights Growth and Challenges

Krystal Biotech, Inc. (($KRYS)) has held its Q3 earnings call. Read on for the main highlights of the...

4d ago

KRYS

Hold Rating Maintained Amid Mixed Market Performance and Future Pipeline Potential

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Hold rating on Krystal Biotech, with a...

5d ago

KRYS

Krystal Biotech Reports Strong Q3 2025 Performance

Krystal Biotech, Inc. ( ($KRYS) ) has released its Q3 earnings. Here is a breakdown of the information...

5d ago

KRYS

Krystal Biotech’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Krystal Biotech, retaining the price target of...

5d ago

KRYS

Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating yesterday....

5d ago

KRYS

KRYS Earnings this Week: How Will it Perform?

Krystal Biotech, Inc. (KRYS) is scheduled to report 3rd quarter earnings on 11/03/2025, before the market opens. Regarding...

8d ago

KRYS

KRYS FAQ

What was Krystal Biotech’s price range in the past 12 months?

Krystal Biotech lowest stock price was $122.80 and its highest was $212.98 in the past 12 months.

What is Krystal Biotech’s market cap?

Krystal Biotech’s market cap is $5.80B.

When is Krystal Biotech’s upcoming earnings report date?

Krystal Biotech’s upcoming earnings report date is Mar 02, 2026 which is in 113 days.

How were Krystal Biotech’s earnings last quarter?

Krystal Biotech released its earnings results on Nov 03, 2025. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.09 by $1.57.

Is Krystal Biotech overvalued?

According to Wall Street analysts Krystal Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Krystal Biotech pay dividends?

Krystal Biotech does not currently pay dividends.

What is Krystal Biotech’s EPS estimate?

Krystal Biotech’s EPS estimate is 1.5.

How many shares outstanding does Krystal Biotech have?

Krystal Biotech has 28,997,519 shares outstanding.

What happened to Krystal Biotech’s price movement after its last earnings report?

Krystal Biotech reported an EPS of $2.66 in its last earnings report, beating expectations of $1.09. Following the earnings report the stock price went up 0.172%.

Which hedge fund is a major shareholder of Krystal Biotech?

Currently, no hedge funds are holding shares in KRYS

Krystal Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.66%

Trailing 12-Months

Asset Growth

26.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Krystal Biotech

Krystal Biotech, Inc. is a biotechnology company specializing in developing innovative gene therapies for the treatment of rare diseases, particularly those affecting the skin. The company focuses on its lead product candidate, KB103, which is designed to address dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. Krystal Biotech utilizes its proprietary Skin Drug Delivery System (SDDS) technology to deliver genes directly to the skin, aiming to improve the lives of patients with genetic skin disorders.

Krystal Biotech (KRYS) Earnings & Revenues

Historic Earnings Reports

KRYS Company Deck

KRYS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Krystal Biotech demonstrated strong financial performance with significant revenue growth and successful international expansion. However, challenges remain in achieving full market penetration and optimizing margins globally.View all KRYS earnings summaries

KRYS Stock 12 Month Forecast

Average Price Target

$221.00

▲(11.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","157":"$157","190":"$190","223":"$223","256":"$256"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$255.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":221,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$221.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$198.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,157,190,223,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,201.9323076923077,206.35461538461539,210.77692307692308,215.19923076923075,219.62153846153845,224.04384615384615,228.46615384615384,232.88846153846154,237.3107692307692,241.7330769230769,246.1553846153846,250.5776923076923,{"y":255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,199.31692307692308,201.12384615384616,202.93076923076922,204.7376923076923,206.54461538461538,208.35153846153847,210.15846153846152,211.9653846153846,213.7723076923077,215.57923076923078,217.38615384615383,219.19307692307692,{"y":221,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,197.5476923076923,197.5853846153846,197.62307692307692,197.66076923076923,197.69846153846154,197.73615384615385,197.77384615384614,197.81153846153845,197.84923076923076,197.88692307692307,197.92461538461538,197.9623076923077,{"y":198,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":176.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >